Form 144 Filer Information SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 144

**FORM 144** 

NOTICE OF PROPOSED SALE OF SECURITIES

PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

### 144: Filer Information

Filer CIK 0002042910
Filer CCC XXXXXXXX
Is this a LIVE or TEST Filing? • LIVE • TEST

Submission Contact Information

Name

Phone

E-Mail Address

### 144: Issuer Information

Name of Issuer Aura Biosciences, Inc.

SEC File Number 001-40971

80 Guest Street

Address of Issuer

Boston

**MASSACHUSETTS** 

02135

Phone 617-500-8864

Name of Person for Whose Account the Securities are To Be Sold Elazzouzi Amy

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer Officer

### 144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value		Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC Drive 200 West Civic Center 4th Floor Sandy UT 84070	1001	7679.15	49951466	01/21/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

## 144: Securities To Be Sold

Title of the	Date you	Nature of	Name of	Is	Date	Amount of	Date of	Nature of
Class	Acquired	Acquisition	Person from	this	Donor	Securities	Payment	Payment *

	Transaction	Whom Acquired	a Acquired	Acquired	
Common Stock 01/19/2023	Restricted Stock unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan, subject to vesting requirements.	Aura Biosciences, Inc.		2844	01/19/2023 N/A

<sup>\*</sup> If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

# 144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of	Securities Sold	<b>Gross Proceeds</b>
Amy Elazzouzi 80 Guest Street	Common Stock	10/29/2024 553	3	5938.41
Boston MA 02135	Common Stock	10/25/2021 333	,	2,20.11

Amount of

## 144: Remarks and Signature

The sales reported on this Form 144 represent the number of shares required to be sold by the Reporting Person to Remarks cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

Date of Notice

01/21/2025

**ATTENTION:** 

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature Amy Elazzouzi

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)